Brought to you by 
PhoreMost gets £11mm in Series A round
18 May 2018
Executive Summary
UK drug discovery start-up PhoreMost Ltd. raised £11mm ($15mm) in its Series A financing led by returning shareholders Jonathan Milner, Amadeus Capital Partners, Cambridge Enterprise, and Parkwalk Advisors, and first-time backer Morningside Ventures. A representative from Parkwalk and Morningside will join the board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PhoreMost gets £11mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice